| Company Name: |
J & K SCIENTIFIC LTD.
|
| Tel: |
18210857532; 18210857532 |
| Email: |
jkinfo@jkchemical.com |
| Products Intro: |
Product Name:ValnoctaMide
CAS:4171-13-5
Package:100Mg,1g,25Mg
|
valnoctamide manufacturers
- Valnoctamide
-
- $29.00 / 2mg
-
2025-12-04
- CAS:4171-13-5
- Min. Order:
- Purity: 98.00%
- Supply Ability: 10g
- valnoctamide
-
- $1.00 / 1KG
-
2019-12-27
- CAS:4171-13-5
- Min. Order: 1KG
- Purity: 97%-99.9%
- Supply Ability: 100kg
|
| | valnoctamide Basic information |
| | valnoctamide Chemical Properties |
| Melting point | 113.5-1140C | | Boiling point | 261.35°C (rough estimate) | | density | 0.9636 (rough estimate) | | refractive index | 1.4614 (estimate) | | storage temp. | Refrigerator | | solubility | DMSO: soluble20mg/mL, clear | | form | powder | | pka | 16.81±0.50(Predicted) | | color | white to off-white | | Water Solubility | 8.70g/L(temperature not stated) |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 | | RTECS | YV5950000 | | Toxicity | LD50 oral in rat: 760mg/kg |
| | valnoctamide Usage And Synthesis |
| Description | Valnoctamide is an isomer of the valproic acid amide, valpromide. It has been marketed as an anxiolytic and sedative compound and suppresses neuropathic pain. Unlike valpromide, valnoctamide is not metabolized to its acid form, valnoctic acid, in vivo and has no teratogenicity. It abolishes the activity of myo-inositol-1-phosphate synthase in human brain crude homogenates (Ki = 0.18 mM). Valnoctamide suppresses electrographic seizures in animal models of status epilepticus, suggesting potential applications in managing epilepsy. | | Chemical Properties | Crystalline Solid | | Uses | Isomer of Valpromide. Anxiolytic. | | Definition | ChEBI: Valnoctamide is a fatty amide. | | Brand name | Axiquel (Ortho-McNeil). | | References | [1] ROGAWSKI M A. Diverse mechanisms of antiepileptic drugs in the development pipeline[J]. Epilepsy Research, 2006, 69 3: Pages 273-294. DOI: 10.1016/j.eplepsyres.2006.02.004
[2] ILAN WINKLER. Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain[J]. British Journal of Pharmacology, 2009, 146 2: 198-208. DOI: 10.1038/sj.bjp.0706310
[3] GALIT SHALTIEL. Effect of valproate derivatives on human brain myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing.[J]. Pharmacological Reports, 2007, 59 4: 402-407.
[4] JAY SPAMPANATO F. E D. Valnoctamide enhances phasic inhibition: A potential target mechanism for the treatment of benzodiazepine-refractory status epilepticus[J]. Epilepsia, 2014, 55 9: e94-e98. DOI: 10.1111/epi.12702 |
| | valnoctamide Preparation Products And Raw materials |
|